Cerca
image du produit
Journal of the American Academy of Dermatology

Abbonarsi

A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars - 18/06/14

Doi : 10.1016/j.jaad.2014.02.034 
Jwala Karnik, MD a, Leslie Baumann, MD l, Suzanne Bruce, MD b, Valerie Callender, MD c, d, Steven Cohen, MD e, f, Pearl Grimes, MD m, John Joseph, MD h, Ava Shamban, MD i, James Spencer, MD j, Ruth Tedaldi, MD n, William Philip Werschler, MD k, Stacy R. Smith, MD g, ⁎
a Suneva Medical Inc, Santa Barbara, California 
b Suzanne Bruce and Associates, Houston, Texas 
c Callender Dermatology and Cosmetic Center, Glenn Dale, Maryland 
d Howard University College of Medicine, Washington, District of Columbia 
e FACES+ Plastic Surgery, Skin, and Laser Center, San Diego, California 
f Division of Plastic Surgery, University of California, San Diego, California 
g Division of Dermatology, University of California, San Diego, California 
h Clinical Testing Center of Beverly Hills, CA, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California 
i University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California 
j Mount Sinai School of Medicine, New York, New York 
k Division of Dermatology University of Washington School of Medicine, Seattle, Washington 
l Baumann Cosmetic and Research Institute, Miami, Florida 
m Vitiligo & Pigmentation Institute of Southern California, University of California, Los Angeles Geffen School of Medicine, Los Angeles, California 
n private practice, Wellesley, Massachusetts 

∗Reprint requests: Stacy R. Smith, MD, 561 Saxony Place, Suite 102, Encinitas, CA 92024.

Abstract

Background

Acne scarring remains a stubborn clinical problem. Few treatments have been shown to be definitely effective for this problem. Polymethylmethacrylate (PMMA) microspheres in collagen (ArteFill, Suneva Medical Inc, Santa Barbara, CA) have shown long-term benefit for nasolabial fold treatment. A pilot study has shown benefit for PMMA-collagen in atrophic acne scarring.

Objective

We sought to demonstrate the safety and effectiveness of PMMA-collagen for acne scarring in a controlled, blinded trial.

Methods

Subjects with at least 4 moderate to severe rolling, atrophic scars randomly received PMMA-collagen or saline injections. Subjects underwent up to 2 injection sessions and were followed up for 6 months. Efficacy was assessed using a validated rating scale for each scar.

Results

In all, 147 subjects underwent injections. Success was achieved by 64% of those treated with PMMA-collagen compared with 33% of control subjects (P = .0005). The treatment showed excellent safety with generally mild, reversible adverse events. No significant differences in efficacy or safety were noted between genders, for darker skin types, or in older age groups.

Limitations

Subjects were followed up for only 6 months.

Conclusion

PMMA-collagen demonstrates substantial effectiveness in the treatment of atrophic acne scars of the face while maintaining an excellent safety profile. Further follow-up should be undertaken to demonstrate longer-term benefit and safety.

Il testo completo di questo articolo è disponibile in PDF.

Key words : acne, acne scars, collagen, dermal filler, microspheres, polymethylmethacrylate

Abbreviations used : AE, ASRS, FDA, PMMA


Mappa


 Supported by Suneva Medical Inc.
 Conflicts of interest: None declared.


© 2014  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

    •

  • Contenuto

    •

Vol 71 - N° 1

P. 77-83 - luglio 2014 Ritorno al numero
Articolo precedente Articolo precedente
  • A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: Investigating practice gaps and potential cost-savings
  • Young H. Lee, Guodong Liu, Diane M. Thiboutot, Douglas L. Leslie, Joslyn S. Kirby
| Articolo seguente Articolo seguente
  • A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus
  • Deana Funaro, Audrey Lovett, Nathalie Leroux, Julie Powell

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account

Aide & support

Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.

Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.